"From evidence to practice" - Insights from the multidisciplinary team on the optimal integration of GLP-1 receptor agonists in obesity management services

被引：1
作者：
Brown, Adrian [1 ,2 ,3 ]
Mellor, Duane [4 ,5 ]
Makaronidis, Janine [1 ,2 ,6 ]
Shuttlewood, Emma [7 ]
Miras, Alexander Dimitri [8 ]
Pournaras, Dimitri J. [9 ]
机构：
[1] UCL, Ctr Obes Res, London, England
[2] Univ Coll London Hosp NHS Trust, Bariatr Ctr Weight Management & Metab Surg, London, England
[3] Univ Coll London Hosp, Biomed Res Ctr, Natl Inst Hlth & Care Res, London, England
[4] Univ Hosp Leicester NHS Trust, Nutr & Dietet, Leicester, England
[5] Aston Univ, Aston Med Sch, Birmingham, England
[6] Barts Hlth NHS Trust, Royal London Hosp, Dept Diabet & Metab, London, England
[7] Univ Hosp Coventry & Warwickshire NHS Trust, Specialist Weight Management Serv, Coventry, England
[8] Ulster Univ, Sch Nursing, Derry, North Ireland
[9] North Bristol Natl Hlth Serv Trust, Dept Bariatr & Metab Surg, Bristol, England
来源：
NUTRITION BULLETIN | 2024年 / 49卷 / 03期
关键词：
WEIGHT-LOSS MAINTENANCE; DOUBLE-BLIND; 3.0; MG; LIRAGLUTIDE; EFFICACY; PLACEBO; SAFETY; REGAIN; TRIAL;
D O I：
10.1111/nbu.12700
中图分类号：
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号：
100403 ;
摘要：
引用
收藏
页码：257 / 263
页数：7
相关论文
共 50 条
[31]   Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients [J].
Levy, Shauna ;
Attia, Abdallah ;
Elshazli, Rami M. ;
Abdelmaksoud, Ahmed ;
Tatum, Danielle ;
Aiash, Hani ;
Toraih, Eman A. .
CANCERS, 2025, 17 (01)
[32]   Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of EXSCEL [J].
Gooding, Kim M. ;
Stevens, Susanna ;
Lokhnygina, Yuliya ;
Giczewska, Anna ;
Shore, Angela C. ;
Holman, Rury R. .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 212
[33]   Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection [J].
Laura C. Page ;
Michael Freemark .
Current Obesity Reports, 2020, 9 :391-401
[34]   An overview of the once-weekly GLP-1 receptor agonists from the pharmacist's perspective [J].
Patel, Dhiren .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 :3-6
[35]   Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events? [J].
Murphy, Conor F. ;
le Roux, Carel W. .
ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (10)
[36]   Experts discuss their Daily practice with GLP-1 Receptor Agonists Continuously well adjusted with Exenatide 1 x weekly [J].
Buchholz, Gabriele ;
Burchert, Dieter ;
Frank, Matthias ;
Schlecht, Karin .
DIABETES STOFFWECHSEL UND HERZ, 2012, 21 (06) :A1-+
[37]   Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role? [J].
Bellary, Srikanth ;
Tahrani, Abd A. ;
Barnett, Anthony H. .
LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (11) :870-871
[38]   Adverse drug reaction patterns of GLP-1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database [J].
Kim, Tae Hyeon ;
Lee, Kyeongmin ;
Park, Seoyoung ;
Oh, Jiyeon ;
Park, Jaeyu ;
Jo, Hyesu ;
Lee, Hayeon ;
Cho, Jaehyeong ;
Wen, Xuerong ;
Cho, Hanseul ;
Kim, Sunyoung ;
Yon, Dong Keon .
DIABETES OBESITY & METABOLISM, 2025, :3490-3502
[39]   GLP-1 receptor agonists in type 2 diabetes NICE guidelines versus clinical practice [J].
Thong, Ken Y. ;
Gupta, Piya S. ;
Cull, Melissa L. ;
Adamson, Karen A. ;
Dove, David S. ;
Rowles, Susannah V. ;
Tarpey, Stephanie ;
Duncan, Catriona ;
Chalmers, John ;
Harper, Roy ;
McDonald, Paula ;
Brennan, Ursula ;
Walton, Chris ;
Ryder, Robert E. J. .
BRITISH JOURNAL OF DIABETES AND VASCULAR DISEASE, 2014, 14 (02) :52-+
[40]   New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists [J].
Sztanek, Ferenc ;
Toth, Laszlo Imre ;
Peto, Attila ;
Hernyak, Marcell ;
Dioszegi, Agnes ;
Harangi, Mariann .
BIOMEDICINES, 2024, 12 (06)
12345